Risk factor
Poor trading liquidity
Profitability factor
Very low or no dividends
About
Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology,...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD
Target Price
The average target price of SLV.WA is 52 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell